TIPIRACIL HYDROCHLORIDE AND TRIFLURIDINE Drug Patent Profile
Which patents cover Tipiracil Hydrochloride And Trifluridine, and what generic alternatives are available?
Tipiracil Hydrochloride And Trifluridine is a drug marketed by MSN and Natco and is included in two NDAs.
The generic ingredient in TIPIRACIL HYDROCHLORIDE AND TRIFLURIDINE is tipiracil hydrochloride; trifluridine. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the tipiracil hydrochloride; trifluridine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Tipiracil Hydrochloride And Trifluridine
A generic version of TIPIRACIL HYDROCHLORIDE AND TRIFLURIDINE was approved as tipiracil hydrochloride; trifluridine by NATCO on June 13th, 2023.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for TIPIRACIL HYDROCHLORIDE AND TRIFLURIDINE?
- What are the global sales for TIPIRACIL HYDROCHLORIDE AND TRIFLURIDINE?
- What is Average Wholesale Price for TIPIRACIL HYDROCHLORIDE AND TRIFLURIDINE?
Summary for TIPIRACIL HYDROCHLORIDE AND TRIFLURIDINE
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 2 |
| Clinical Trials: | 94 |
| Patent Applications: | 837 |
| DailyMed Link: | TIPIRACIL HYDROCHLORIDE AND TRIFLURIDINE at DailyMed |
Recent Clinical Trials for TIPIRACIL HYDROCHLORIDE AND TRIFLURIDINE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| National Cancer Institute (NCI) | PHASE2 |
| Federation Francophone de Cancerologie Digestive | PHASE3 |
| Takeda Development Center Americas, Inc. | PHASE3 |
See all TIPIRACIL HYDROCHLORIDE AND TRIFLURIDINE clinical trials
US Patents and Regulatory Information for TIPIRACIL HYDROCHLORIDE AND TRIFLURIDINE
Trifluridine and Tipiracil Hydrochloride Market Dynamics, Sales Outlook, and Patent Exclusivity
Trifluridine/tipiracil hydrochloride, marketed as Lonsurf, is an oral antimetabolite combination developed by Taiho Pharmaceutical and commercialized outside Japan through Servier. Its core market is previously treated metastatic colorectal cancer and gastric or gastroesophageal junction cancer. The combination gained a major commercial expansion in 2023 when the FDA approved Lonsurf with bevacizumab for metastatic colorectal cancer after prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based therapy, an anti-VEGF agent, and an anti-EGFR antibody when clinically indicated.[1]
The product has durable demand because it is an oral treatment with demonstrated survival benefit in heavily pretreated disease. Its main commercial constraints are late-line positioning, myelosuppression, competition from regorafenib and fruquintinib, and eventual generic risk after key U.S. patent protection expires.
What is trifluridine/tipiracil hydrochloride and how is it used?
Trifluridine/tipiracil is a fixed-dose oral combination consisting of trifluridine, the cytotoxic active component, and tipiracil hydrochloride, which inhibits trifluridine degradation and increases systemic exposure.
The FDA-approved regimen is generally administered twice daily on Days 1 through 5 and Days 8 through 12 of each 28-day cycle. The approved tablet strengths are:
| Tablet strength | Trifluridine content | Tipiracil hydrochloride content |
|---|---|---|
| 15 mg/6.14 mg | 15 mg | 6.14 mg |
| 20 mg/8.19 mg | 20 mg | 8.19 mg |
The principal indications are:
- Metastatic colorectal cancer previously treated with fluoropyrimidine, oxaliplatin, irinotecan, an anti-VEGF biologic, and an anti-EGFR monoclonal antibody when appropriate.
- Metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior systemic regimens.
- Metastatic colorectal cancer in combination with bevacizumab after progression on standard chemotherapy and biologic therapy.[1]
The combination is not a broad first-line colorectal cancer product. Its value is concentrated in later treatment lines, where maintaining treatment tolerability and preserving oral administration are important.
What clinical evidence supports the Lonsurf market?
The pivotal RECOURSE trial established trifluridine/tipiracil as a treatment for refractory metastatic colorectal cancer. In that study, median overall survival was 7.1 months with Lonsurf compared with 5.3 months with placebo. Median progression-free survival was 2.0 months compared with 1.7 months.[2]
The TAGS trial supported the gastric and gastroesophageal junction indication. Median overall survival was 5.7 months with Lonsurf compared with 3.6 months with placebo.[3]
The SUNLIGHT trial materially improved the product’s commercial position. Lonsurf plus bevacizumab produced median overall survival of 10.8 months compared with 7.5 months for Lonsurf alone in patients with metastatic colorectal cancer after progression on standard therapies. Median progression-free survival was 5.6 months compared with 2.4 months.[4]
Why the bevacizumab combination matters commercially
Before SUNLIGHT, Lonsurf was primarily a single-agent late-line therapy. The combination approval created a higher-value regimen with:
- A stronger overall-survival profile.
- Greater physician adoption in refractory colorectal cancer.
- Higher drug utilization per treated patient.
- A commercial opportunity tied to both Lonsurf and bevacizumab use.
- A clearer position against regorafenib and other late-line therapies.
The combination also increases the importance of treatment sequencing. Physicians may use Lonsurf plus bevacizumab before or instead of regorafenib or fruquintinib, depending on prior exposure, tolerability, biomarker status, access, and local guidelines.
How large is the market for trifluridine/tipiracil?
The addressable market is concentrated in advanced colorectal and gastric cancers.
| Market driver | Commercial effect |
|---|---|
| High incidence of colorectal cancer | Creates a large pool of patients reaching later treatment lines |
| Improved first- and second-line therapy | Can increase the number of patients surviving long enough to receive Lonsurf |
| Oral administration | Supports outpatient use and reduces infusion burden |
| Combination with bevacizumab | Raises clinical relevance and treatment value |
| Late-line positioning | Limits duration of therapy and total revenue per patient |
| Myelosuppression | Can cause dose interruptions, reductions, and treatment discontinuation |
| Regorafenib and fruquintinib | Creates direct competition in refractory colorectal cancer |
| Generic entry | Creates the largest long-term pricing risk |
The colorectal cancer opportunity is larger than the gastric cancer opportunity in most major markets. The gastric indication expands the patient base but does not have the same commercial scale as metastatic colorectal cancer.
What are the sales and financial trends for Lonsurf?
Lonsurf has moved from a niche salvage product toward a broader late-line colorectal cancer franchise. The most important financial catalyst was the FDA approval of the bevacizumab combination in August 2023.[5]
Taiho reports Japanese and international pharmaceutical performance in its corporate disclosures, while Servier reports international commercialization outside Taiho-controlled territories. Revenue figures differ by reporting entity, geography, currency, and whether they represent product sales, net sales, or consolidated revenue.
The financial trajectory can be summarized as follows:
| Period | Market position | Financial implication |
|---|---|---|
| 2015-2018 | Initial metastatic colorectal cancer launch | Early adoption and reimbursement buildout |
| 2019-2022 | Gastric cancer expansion and broader international penetration | More stable multi-indication revenue |
| 2023 | FDA approval of Lonsurf plus bevacizumab | Major volume and treatment-duration catalyst |
| 2024 onward | Post-SUNLIGHT adoption and competitive repositioning | Growth depends on guideline uptake and payer access |
| Patent-loss period | Generic or authorized-generic pressure | Price and market-share compression |
Taiho has identified Lonsurf as one of its principal growth products. Servier has also included Lonsurf among its major oncology brands. The product’s revenue base benefits from a mature manufacturing platform and established prescribing behavior, but it remains exposed to a finite late-line patient population and relatively short median treatment durations.[6][7]
What drives revenue per patient?
Revenue depends on:
- Patient weight and body-surface-area-based dosing.
- Number of treatment cycles.
- Dose reductions caused by neutropenia, anemia, or thrombocytopenia.
- Use as monotherapy or with bevacizumab.
- Net price after rebates and discounts.
- Country-specific reimbursement.
- Earlier adoption of the SUNLIGHT regimen.
The combination regimen can increase product demand without changing the tablet dose. Bevacizumab revenue accrues to the biologic manufacturer and does not automatically translate into Lonsurf revenue, but combination use can extend Lonsurf’s treatment relevance.
How does trifluridine/tipiracil compare with competing colorectal cancer drugs?
The primary competitors in refractory metastatic colorectal cancer are regorafenib, fruquintinib, and other approved or guideline-supported later-line treatments.
| Product | Active ingredient | Main positioning | Commercial advantage | Main constraint |
|---|---|---|---|---|
| Lonsurf | Trifluridine/tipiracil | Refractory metastatic colorectal and gastric cancer | Oral therapy; survival data; bevacizumab combination | Myelosuppression |
| Stivarga | Regorafenib | Refractory metastatic colorectal cancer and other tumors | Established market presence | Hand-foot syndrome, fatigue, hypertension, liver toxicity |
| Fruzaqla | Fruquintinib | Previously treated metastatic colorectal cancer | Selective VEGFR profile and newer U.S. launch | Newer reimbursement and adoption cycle |
| Lonsurf plus bevacizumab | Trifluridine/tipiracil plus bevacizumab | Later-line metastatic colorectal cancer | SUNLIGHT survival benefit | Requires combination management and monitoring |
The most direct competitive threat is fruquintinib in patients eligible for vascular endothelial growth factor receptor-directed therapy. Regorafenib remains a recognized alternative, although tolerability can influence sequencing.
Lonsurf’s strongest differentiation is its survival evidence in combination with bevacizumab. Its principal weakness is hematologic toxicity, particularly neutropenia, which requires blood-count monitoring and can affect dose intensity.
What is the FDA regulatory status of trifluridine/tipiracil?
The FDA approved Lonsurf in September 2015 for previously treated metastatic colorectal cancer. The agency expanded the label in February 2019 to include metastatic gastric or gastroesophageal junction adenocarcinoma after at least two prior systemic therapies.[1]
In August 2023, the FDA approved Lonsurf with bevacizumab for metastatic colorectal cancer after progression on specified prior regimens.[5]
The product is regulated as a small-molecule prescription drug. It is not a biologic and therefore does not face a biosimilar pathway. A competing product would generally enter through an abbreviated new drug application, subject to pharmaceutical-equivalence, bioequivalence, labeling, manufacturing, and patent-certification requirements.
What patents protect trifluridine/tipiracil and Lonsurf?
Lonsurf’s patent estate includes composition, pharmaceutical-combination, formulation, and use-related claims. The most commercially important protection is the U.S. patent coverage directed to the trifluridine/tipiracil combination and its use in cancer treatment.
Public patent records and Orange Book information identify U.S. patents associated with Lonsurf, including patents in the US 8,236,935 and related patent families. Expiration dates vary by patent, jurisdiction, patent-term adjustment, and any pediatric exclusivity or regulatory extensions. The practical loss-of-exclusivity date therefore depends on the specific Orange Book listing and the scope of any surviving claims.[8]
What formulations are protected?
The core formulation is the fixed-dose oral tablet containing trifluridine and tipiracil hydrochloride. Patent claims may cover:
- The active-ingredient combination.
- Specific ratios of trifluridine to tipiracil.
- Pharmaceutical compositions and excipients.
- Oral tablet formulations.
- Dosing regimens for cancer treatment.
- Use in colorectal, gastric, or gastroesophageal cancers.
A generic applicant could challenge one or more listed patents while preserving noninfringing claims. The commercial outcome would depend on the strength of the asserted claims, patent construction, prior art, and any settlement terms.
What method-of-use patents are relevant?
Method-of-use protection can cover administering the combination to patients with previously treated metastatic colorectal cancer or gastric cancer. The 2023 approval of Lonsurf plus bevacizumab also creates a strategic distinction between:
- Lonsurf monotherapy.
- Lonsurf combined with bevacizumab.
- Use after defined prior treatment sequences.
- Use at specific dosing schedules.
Method-of-use claims can be commercially weaker than composition claims if generic manufacturers use skinny labeling that excludes patented indications. Their value depends on prescribing behavior and whether the patented use is difficult to avoid in practice.
When does trifluridine/tipiracil lose exclusivity?
FDA marketing exclusivity and patent exclusivity are separate.
| Protection | Relevance |
|---|---|
| New chemical entity exclusivity | The original product received the standard small-molecule regulatory exclusivity period |
| Orphan-drug exclusivity | Not the principal basis of Lonsurf’s colorectal market protection |
| Patent exclusivity | Determines the principal timing of generic entry |
| Pediatric exclusivity | May extend eligible patent or exclusivity periods if granted |
| Method-of-use protection | Can delay or limit approved generic labeling for specific indications |
The original regulatory exclusivity period has expired. The remaining commercial barrier is patent protection and the ability of generic applicants to obtain approval without infringing enforceable claims.
The key risk period is the late 2020s and early 2030s, depending on the patent family, patent-term adjustment, Orange Book listing, and litigation outcomes. A single headline expiration date does not describe the full estate because different patents can expire at different times.
Which companies are challenging Lonsurf exclusivity?
Generic-drug manufacturers are the likely challengers because trifluridine/tipiracil is an oral small-molecule product suitable for an abbreviated approval pathway. Potential entrants include large generic manufacturers with oncology tablet capabilities and established U.S. commercial infrastructure.
A Paragraph IV challenge would require the applicant to certify that a listed patent is invalid, unenforceable, or not infringed. The patent holder could then file an infringement action, potentially triggering a statutory stay of FDA approval for up to 30 months under the Hatch-Waxman framework.[9]
The commercial impact of a challenge would depend on:
- The number of asserted patents.
- Whether the challenge targets composition or only use claims.
- The filing date of the first substantially complete ANDA.
- The availability of 180-day generic exclusivity.
- Whether the parties settle before trial.
- Whether a court grants a preliminary or permanent injunction.
No biosimilar challenge is relevant because Lonsurf is a chemically synthesized small-molecule drug.
What patent litigation and settlement risks affect generic launch?
The most consequential litigation risk is an ANDA case involving the composition or combination patent. A successful patent challenge could permit an earlier launch than the latest listed expiration date. A successful infringement case could delay entry until patent expiry or a negotiated settlement date.
Potential settlement structures include:
- Entry on the patent expiration date.
- Authorized-generic supply by the originator or licensee.
- Royalty-bearing early entry.
- Entry limited to nonprotected indications.
- Geographic restrictions.
- No-admission provisions.
Settlement terms are material to valuation because a settlement can convert uncertain litigation timing into a defined entry date. They can also preserve a portion of branded revenue if the generic enters with limited indications or through an authorized-generic arrangement.
What manufacturing and intellectual-property barriers exist?
Manufacturing barriers are moderate rather than biologic-level. The product is an oral tablet, but oncology manufacturing still requires:
- Consistent control of two active ingredients.
- Stability and impurity control.
- Validated content uniformity.
- High-potency handling procedures.
- Reliable supply of trifluridine and tipiracil hydrochloride.
- Compliance with FDA current good manufacturing practice requirements.
The combination’s manufacturing complexity is lower than that of injectable biologics, antibody-drug conjugates, or cell therapies. Patent barriers, regulatory data, bioequivalence, and commercial scale are therefore more important than process complexity.
What generic launch scenarios exist for Lonsurf?
Three scenarios are commercially plausible.
Scenario 1: Patent-protected launch after the primary estate expires
Generic manufacturers wait for the final enforceable composition or formulation patent to expire. This produces the cleanest entry but gives the branded product more time to convert patients and defend market share.
Scenario 2: Litigation-driven early entry
A generic applicant challenges a listed patent and obtains a favorable judgment or settlement. Entry occurs before the latest listed expiry, causing rapid price erosion.
Scenario 3: Limited-label entry
A generic launches with labeling that excludes patented method-of-use claims. This can preserve some branded use, particularly where physicians prescribe the product according to the patented regimen or combination.
For valuation purposes, the key sensitivity is not only the entry year. It is the number of entrants in the first 12 months. One generic entrant can cause substantial price pressure; multiple entrants typically accelerate discounts and formulary substitution.
What is the geographic coverage of trifluridine/tipiracil?
Lonsurf is commercialized in major oncology markets, including the United States, Japan, and European markets. Taiho has historically controlled development and commercialization in Japan and selected territories, while Servier has commercial responsibility in many markets outside Japan and certain other regions.[6][7]
Patent coverage is jurisdiction-specific. The U.S. patent position does not determine entry timing in Europe, Japan, China, or other markets. Key geographic variables include:
- National patent expiration.
- Supplementary protection certificates in Europe.
- Patent-term adjustment.
- Local regulatory exclusivity.
- Reimbursement approval.
- Local manufacturing and supply arrangements.
- National litigation and settlement terms.
A company can face U.S. generic exposure while retaining stronger protection or higher net pricing in selected international markets.
How strong is the patent estate for trifluridine/tipiracil?
The estate is commercially meaningful but not impenetrable.
| Estate characteristic | Assessment |
|---|---|
| Composition protection | Strongest protection if claims remain valid and cover the fixed-dose combination |
| Formulation protection | Useful but potentially vulnerable to design-around strategies |
| Method-of-use protection | Valuable where treatment sequencing is central to prescribing |
| Manufacturing protection | Can raise supply barriers but may not prevent all generic production |
| Regulatory exclusivity | Largely exhausted for the original U.S. launch |
| Biosimilar protection | Not applicable |
| Generic substitution risk | High after enforceable composition protection expires |
The estate’s strength is supported by multiple claim categories and broad clinical use. Its weakness is that the product is a small-molecule tablet with a conventional generic pathway. Once core composition protection falls away, the market can become accessible to several manufacturers.
What is the revenue exposure to patent expiry?
Lonsurf revenue is exposed to patent expiry across three channels:
- Volume displacement by generic tablets.
- Net-price erosion through payer substitution.
- Reduced ability to sustain premium pricing for monotherapy and combination use.
The branded company can mitigate exposure by:
- Increasing use of the bevacizumab combination.
- Expanding geographic access.
- Developing next-generation oral oncology products.
- Negotiating authorized-generic arrangements.
- Retaining indication-specific method-of-use protection.
- Using real-world evidence to preserve guideline preference.
The strongest period for revenue expansion is the post-SUNLIGHT adoption window before meaningful generic entry. The main downside risk is that generic applicants challenge composition patents earlier than expected and secure a favorable settlement or court decision.
Key Takeaways
- Trifluridine/tipiracil hydrochloride is marketed as Lonsurf and is owned commercially by Taiho and Servier across different territories.
- The largest market is refractory metastatic colorectal cancer.
- The 2023 FDA approval of Lonsurf plus bevacizumab materially improved the product’s clinical and commercial position.
- SUNLIGHT is the central growth catalyst, with median overall survival of 10.8 months for the combination versus 7.5 months for Lonsurf alone.
- Regorafenib and fruquintinib are the principal competing late-line colorectal cancer therapies.
- The product is a small-molecule tablet, so biosimilar risk does not apply. Generic ANDA risk does.
- Core patent protection, Orange Book listings, Paragraph IV challenges, and settlement timing will determine the practical loss-of-exclusivity date.
- Revenue should remain supported by post-SUNLIGHT adoption before patent-driven generic competition intensifies.
- Manufacturing barriers are moderate. Patent scope, regulatory approval, bioequivalence, and commercial scale are the principal entry barriers.
- The financial downside after generic entry will depend heavily on the number of initial entrants and whether method-of-use claims constrain substitution.
Frequently Asked Questions
Is trifluridine/tipiracil the same drug as Lonsurf?
Yes. Lonsurf is the branded product containing trifluridine and tipiracil hydrochloride in fixed-dose oral tablets.
Is Lonsurf a chemotherapy drug or targeted therapy?
It is an oral cytotoxic antimetabolite combination. It is not a biologic and is not classified as a biosimilar-eligible product.
Can Lonsurf be used with bevacizumab?
Yes. The FDA approved Lonsurf plus bevacizumab for previously treated metastatic colorectal cancer in 2023.[5]
What is the principal toxicity limiting Lonsurf sales?
Myelosuppression, especially neutropenia, is the principal treatment-limiting toxicity. Anemia, thrombocytopenia, nausea, fatigue, and infection risk also affect dosing and persistence.[1]
Will generic trifluridine/tipiracil automatically replace branded Lonsurf?
No. Substitution will depend on FDA approval, patent litigation, final labeling, payer policy, state substitution rules, supply reliability, and whether generic products carry the same approved indications.
References
-
U.S. Food and Drug Administration. (2024). Lonsurf (trifluridine and tipiracil) prescribing information. FDA.
-
Mayer, R. J., Van Cutsem, E., Falazarano, A., et al. (2015). Randomized trial of TAS-102 for refractory metastatic colorectal cancer. New England Journal of Medicine, 372(20), 1909-1919.
-
Shitara, K., Doi, T., Dvorkin, M., et al. (2018). Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer. Lancet Oncology, 19(11), 1437-1448.
-
Prager, G. W., Taieb, J., Fakih, M., et al. (2023). Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer. New England Journal of Medicine, 388(18), 1657-1667.
-
U.S. Food and Drug Administration. (2023). FDA approves trifluridine/tipiracil with bevacizumab for metastatic colorectal cancer. FDA.
-
Taiho Pharmaceutical Co., Ltd. (2024). Corporate and financial results disclosures. Taiho Pharmaceutical.
-
Servier. (2024). Annual report and oncology portfolio disclosures. Servier.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
U.S. Code, 21 U.S.C. § 355. (2024). Abbreviated applications and patent certifications under the Hatch-Waxman Act.
More… ↓
